MarketBeat
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
📈
AI Sentiment
Highly Positive
9/10
- Home
- SLDB
as of 02-13-2026 3:45pm EST
$6.21
+$0.13
+2.14%
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 498.6M | IPO Year: | 2018 |
| Target Price: | $14.70 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.41 - $7.37 | Next Earning Date: | 03-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -133171000.0 | FCF Growth: | N/A |
AI-Powered SLDB Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 73.25%
73.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
Hanrahan Jessie
Sell
Chief Regulatory Officer
SLDB Feb 2, 2026
Avg Cost/Share
$6.44
Shares
26,535
Total Value
$170,803.14
Owned After
82,675
SEC Form 4
Brooks Gabriel
Sell
Chief Medical Officer
SLDB Feb 2, 2026
Avg Cost/Share
$6.44
Shares
28,335
Total Value
$182,389.56
Owned After
96,708
SEC Form 4
Howton David T
Sell
Chief Operating Officer
SLDB Feb 2, 2026
Avg Cost/Share
$6.44
Shares
37,771
Total Value
$243,128.15
Owned After
116,753
SEC Form 4
Herzich Paul
Sell
Chief Technology Officer
SLDB Feb 2, 2026
Avg Cost/Share
$6.44
Shares
26,250
Total Value
$168,968.63
Owned After
79,972
SEC Form 4
Cumbo Alexander
Sell
President and CEO
SLDB Feb 2, 2026
Avg Cost/Share
$6.44
Shares
80,258
Total Value
$516,612.72
Owned After
270,931
SEC Form 4
Ganot Ilan
Sell
Director
SLDB Jan 28, 2026
Avg Cost/Share
$6.59
Shares
191
Total Value
$1,258.69
Owned After
17,476
SEC Form 4
Ganot Ilan
Sell
Director
SLDB Jan 5, 2026
Avg Cost/Share
$5.43
Shares
1,053
Total Value
$5,717.79
Owned After
17,476
SEC Form 4
Hanrahan Jessie
Sell
Chief Regulatory Officer
SLDB Dec 3, 2025
Avg Cost/Share
$5.11
Shares
4,483
Total Value
$22,908.13
Owned After
82,675
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Feb 2, 2026 | Sell | $6.44 | 26,535 | $170,803.14 | 82,675 | |
| Brooks Gabriel | SLDB | Chief Medical Officer | Feb 2, 2026 | Sell | $6.44 | 28,335 | $182,389.56 | 96,708 | |
| Howton David T | SLDB | Chief Operating Officer | Feb 2, 2026 | Sell | $6.44 | 37,771 | $243,128.15 | 116,753 | |
| Tan Kevin | SLDB | CFO & Treasurer | Feb 2, 2026 | Sell | $6.44 | 26,837 | $172,747.09 | 108,984 | |
| Herzich Paul | SLDB | Chief Technology Officer | Feb 2, 2026 | Sell | $6.44 | 26,250 | $168,968.63 | 79,972 | |
| Cumbo Alexander | SLDB | President and CEO | Feb 2, 2026 | Sell | $6.44 | 80,258 | $516,612.72 | 270,931 | |
| Ganot Ilan | SLDB | Director | Jan 28, 2026 | Sell | $6.59 | 191 | $1,258.69 | 17,476 | |
| Tan Kevin | SLDB | CFO & Treasurer | Jan 13, 2026 | Sell | $5.27 | 5,704 | $30,060.08 | 108,984 | |
| Ganot Ilan | SLDB | Director | Jan 5, 2026 | Sell | $5.43 | 1,053 | $5,717.79 | 17,476 | |
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Dec 3, 2025 | Sell | $5.11 | 4,483 | $22,908.13 | 82,675 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
MT Newswires
Solid Biosciences Aligns With FDA on Phase 3 Trial Design for Duchenne Muscular Dystrophy Gene Therapy
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
📈
AI Sentiment
Highly Positive
8/10
Compare SLDB vs Leading Stocks
See how SLDB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.